Clinical trials: Peripheral Arterial
Peripheral Artery Disease, Coronary Artery Disease
Routine Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty
1. The prevalence of significant and complex obstructive coronary artery disease (CAD) is high in patients who have low extremity artery disease (LEAD). 2.
- Trial name
- PIROUETTEPTA (NCT02169258)
- Testing
- Systemic Strategy
- Where
- Taiwan
- Volunteers
- 700 people
- Sponsor
- National Cheng-Kung University Hospital
Peripheral Arterial Occlusive Disease
Lifestyle Modification Programme for Patients With Peripheral Arterial Disease
This trial randomises patients with occlusive peripheral arterial disease, to be managed either by providing a 12-week structured lifestyle modification programme, or standard healthcare.
- Trial name
- NCT03935776
- Testing
- Risk Factors Modification Programme, Standard Healthcare
- Where
- Ireland
- Volunteers
- 208 people
- Sponsor
- Western Vascular Institute, Ireland
Peripheral Arterial Disease, Claudication (Finding)
Cilostazol After Lower Extremity Arterial Revascularization Trial
Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days.
- Trial name
- CLEAR (NCT02374957)
- Testing
- Cilostazol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Coronary Artery Disease, Angina Pectoris
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
This is a prospective, single-center study that aims to evaluate the acute and delayed effect of exercise stress testing on the peripheral gene expression (PGE) levels using a predefined gene set established in the Corus CAD…
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- EXERCISE (NCT01486030)
- Testing
- Corus CAD (ASGES)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CardioDx
Acute Ischemic Stroke, Atrial Fibrillation
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
This study aims to compare the effectiveness and safety regarding treatment with standard anticoagulant only or adding antiplatelet to anticoagulant in patients with non-valvular atrial fibrillation and significant…
- Conditions
- Acute Ischemic Stroke, Atrial Fibrillation, Extracranial Atherosclerosis, Intracranial Atherosclerosis
- Trial name
- (ADD-ON) (NCT04010955)
- Testing
- Edoxaban Monotherapy
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Asan Medical Center
Peripheral Artery Disease
Microvascular Reactivity in Peripheral Artery Disease
Peripheral Artery Disease (PAD) is a major risk factor for lower limb amputation. Microvascular reactivity assessed with near-infrared spectrometry has been studied in people with PAD but not in people with limb loss (PLL) who…
- Trial name
- NCT05063474
- Testing
- No Intervention-Clinical Assessments only
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Peripheral Arterial Disease
Clinical Trial Investigating the Efficacy of the Supera Peripheral Stent System for the Treatment of the Common Femoral Artery
The VMI-CFA study investigates the efficacy of the Supera Stent in the treatment of common femoral artery stenosis or occlusion. 100 patients will be included with a RF of 2 to 4.
- Trial name
- VMI-CFA (NCT02804113)
- Testing
- Supera Peripheral Stent System
- Where
- 7 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- ID3 Medical
Peripheral Arterial Disease, Peripheral Vascular Disease
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
- Trial name
- TRANSCEND (NCT03241459)
- Testing
- Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 446 people
- Sponsor
- SurModics, Inc.
Atherosclerosis
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
The purpose of this study is to validate novel assays for serum biomarkers of lipid metabolism (PCSK9 and LDL receptor) and to obtain information about how these biomarkers differ in subjects with normal or high cholesterol levels
- Trial name
- NCT00847782
- Testing
- Blood draw
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Intermittent Claudication
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
Peripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use.
- Trial name
- MOBILE IC (NCT05132439)
- Testing
- Metformin ER
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Peripheral Arterial Disease, Atherosclerotic Lesion
Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease
This first-in-human clinical feasibility study will evaluate the safety and performance of the R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffold and Delivery System in patients undergoing treatment for peripheral…
- Conditions
- Peripheral Arterial Disease, Atherosclerotic Lesion, Lower Extremity Ischemia, Lower Extremity Claudication
- Trial name
- RESOLV I (NCT04912323)
- Testing
- Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold
- Where
- 7 sites in Austria, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- R3 Vascular Inc.
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Peripheral Arterial Disease
Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease
A prospective study, proof-of concept, randomized, controlled, parallel groups, simple blind was performed in 30 male patients (50-60 years old) with Intermittent Claudication (Rutherford category 1-2) recently diagnosed and…
- Trial name
- CLAU (NCT01738542)
- Testing
- Bosentan, Antiaggregant therapy, Statins
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Getafe
Peripheral Arterial Disease
An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies
To evaluate vessel lumen quality (gain) and patient outcomes based on treatment with a predetermined laser treatment protocol in patients presenting with varying lesion types or morphologies: homogenous (plaques with a uniform…
- Trial name
- REX (NCT02921542)
- Testing
- Laser Atherectomy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Spectranetics Corporation
Embolization, Therapeutic
Caterpillar™ Arterial Embolization Device Post-Market Study
The primary objective of this study is to evaluate the performance and safety of the Caterpillar™ Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label…
- Trial name
- MONARCH (NCT04244370)
- Testing
- Caterpillar™ Arterial Embolization Device
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
Near Infrared Spectroscopy Imaging of Change in Tissue Oxygenation to Assess Peripheral Artery Disease
This is a proof-of-concept study with exploratory objective to assess whether superficial tissue oxygenation patterns measured by Snapshot NIRS, in conjunction with the Provocative Elevation Maneuver of the Lower Extremity…
- Trial name
- NCT07397494
- Testing
- Observational study only.
- Volunteers
- 200 people
- Sponsor
- Kent Imaging Inc
PAD
Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease
Sympathetic overactivity partly promotes the development of peripheral artery disease which mainly leads to ischemia of the lower limbs.
- Trial name
- EDPAD (NCT05345431)
- Testing
- endovascular denervation, PTA
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Zhongda Hospital
Chronic Ulcer of Lower Extremity, Wound
Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease
The purpose of this study is to investigate the effect of subcutaneous injection of botulinum toxin A on wound healing caused by lower extremity ischemia.
- Conditions
- Chronic Ulcer of Lower Extremity, Wound, Botulinum Toxins, Type A, Blood Circulation
- Trial name
- NCT06878482
- Testing
- Botulinum toxin A
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Yonsei University
Peripheral Arterial Disease
Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
To evaluate the safety and effectiveness of the Cardio Flow FreedomFlow™ Orbital Circumferential Atherectomy System for atherosclerotic plaque removal and vessel compliance modification in de novo native target lesions in the…
- Trial name
- FASTII (NCT03635190)
- Testing
- Orbital Circumferential Atherectomy
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Cardio Flow, Inc.
Peripheral Arterial Disease
Revascularization of Total or Sub-total Occluded Peripheral Arteries With ByCross® Device. Post Market Clinical Followup
Post market clinical follow up of Bycross® device.
- Trial name
- NCT05110079
- Testing
- ByCross Atherectomy and Thrombectomy
- Where
- 3 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Taryag Medical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.